Eli Lilly Shares Rise on Broker Upgrades, Bullish 2026 Forecasts
Eli Lilly shares advanced after several brokerages upgraded their stance for 2026, reflecting confidence in the company’s late-stage drug pipeline. The bullish revisions follow improved forecast models for its diabetes and obesity franchises.
1. Analyst Upgrades
Multiple brokerages raised recommendations and price targets for Eli Lilly as they turned confident on the 2026 outlook.
2. Drug Pipeline Drivers
Analysts cited strong performance of mid- and late-stage candidates in the company’s diabetes and obesity segments as key growth drivers.
3. Market Reaction
Shares climbed following the upgrades, reflecting investor enthusiasm for the revised earnings and revenue forecasts heading into 2026.
Related News
EXR
Extra Space Storage Adds Retail and Tech Executives with 850-Unit Chain, Ex-Matterport CEO to Board
EXR•
TOL
Toll Brothers Beats Q2 Revenue Guidance by $110M, Raises Delivery and Buyback Plans
TOL•
GS
Goldman Sachs to Lead $1.75 Trillion SpaceX IPO With $1.45B Bitcoin Disclosure
GS•
RLAY
Relay Therapeutics Prices 22.9M Shares at $12 to Raise $275M
RLAY•
GOOG
Google, Blackstone Launch $5B AI Cloud JV with 500MW Capacity by 2027
GOOG•
Sources
F